Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: A population-based analysis

M.P.P. van Herk-Sukel; L.V. van de Poll-Franse; A.C. Voogd; G.A.P. Nieuwenhuijzen; J.W.W. Coebergh; R.M.C. Herings

Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: A population-based analysis

M.P.P. van Herk-Sukel
, L.V. van de Poll-Franse
, A.C. Voogd
, G.A.P. Nieuwenhuijzen
, J.W.W. Coebergh
, R.M.C. Herings

Medical and Clinical Psychology

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Pages (from-to)	843-851
Journal	Breast Cancer Research and Treatment
Volume	122
Issue number	3
Publication status	Published - 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Embargoed Document

Half
266 KB
Embargo ends: 31/12/2099 00:00 CET

Cite this

@article{a7e8a1492356441aaedf6af7239261ee,

title = "Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: A population-based analysis",

author = "\{van Herk-Sukel\}, M.P.P. and \{van de Poll-Franse\}, L.V. and A.C. Voogd and G.A.P. Nieuwenhuijzen and J.W.W. Coebergh and R.M.C. Herings",

year = "2010",

language = "English",

volume = "122",

pages = "843--851",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer",

number = "3",

}

Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: A population-based analysis. / van Herk-Sukel, M.P.P.; van de Poll-Franse, L.V.; Voogd, A.C. et al.
In: Breast Cancer Research and Treatment, Vol. 122, No. 3, 2010, p. 843-851.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years

T2 - A population-based analysis

AU - van Herk-Sukel, M.P.P.

AU - van de Poll-Franse, L.V.

AU - Voogd, A.C.

AU - Nieuwenhuijzen, G.A.P.

AU - Coebergh, J.W.W.

AU - Herings, R.M.C.

PY - 2010

Y1 - 2010

M3 - Article

SN - 0167-6806

VL - 122

SP - 843

EP - 851

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 3

ER -